Cardiovascular disease

Cardiovascular diseaseCoronary heart disease kills more Australians than any other single disease. Many people survive myocardial infarction only to live shorter lives of reduced quality because of the damage to the myocardium that occurs during the infarction.

Heart failure, in which the damaged heart cannot eject sufficient blood, or sudden death due to electrical dysfunction in scarred regions of the heart, are common problems after myocardial infarction.

DDB's work in this area looks at protecting the heart muscle immediately after a myocardial infarction. We are currently identifying and developing G protein-coupled receptor ligands that show desired disease-specific signalling with reduced side effects.

Lab head

Lab name

Research areas

Professor Arthur Christopoulos

G Protein-Coupled receptor allosteric modulation and drug targeting

neuropsychiatric diseases, metabolic and endocrine disorders, cardiovascular disease, allosteric modulation, drug discovery, chemical biology, schizophrenia, Alzheimer’s disease, structural biology, biased agonism

Dr John Haynes

Stem cell biology laboratory

Parkinson's disease, neuroinflammation, neurodegeneration, neuropsychiatric disease, neurodevelopment, Renal disease, Alport Syndrome, cardiovascular disease

Dr Lauren May

Cardiac GPCR pharmacology

cardiovascular disease, heart failure, ischaemia-reperfusion injury, G protein-coupled receptors, adenosine receptors, allosteric modulation, biased agonism, structural biology, molecular modelling, ligand-receptor interactions

Dr Paul White

Cardiac GPCR pharmacology

cardiovascular disease, heart failure, ischaemia-reperfusion injury, G protein-coupled receptors, adenosine receptors, allosteric modulation, biased agonism, structural biology, molecular modelling, ligand-receptor interactions